PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm

A randomised, triple-blind, parallel-group early-phase study (n=30) will compare a single 5 mg oral dose of psilocybin plus Imagery Re-Scripting (ImRS) versus an inert placebo capsule plus ImRS in young people with recent self-harm.

The study tests whether a low, sub-hallucinogenic psilocybin dose enhances toleration of difficult emotions and cognitive flexibility during ImRS, reducing vivid self-harm imagery and associated negative affect compared with ImRS alone.